The UCI confirmed on Wednesday, December 13, that Chris Froome (Team Sky) was notified of an adverse analytical finding (AAF) for salbutamol in excess of 1,000 nanograms per millilitre (ng/ml) in a sample collected during the Vuelta a España this September 7, an event where he went on to win the overall title.
Froome was notified of the AAF on September 20, the same day he finished third in the elite men’s time trial at the UCI Road World Championships in Bergen.
The analysis of the B sample confirmed the results of the rider’s A sample to have 2,000ng/ml of salbutamol, twice WADA’s threshold limit, and the proceedings are being conducted in line with the UCI Anti-Doping Rules, according to a statement from the UCI.
Froome has said previously that he suffered from asthma since he was a child and has used inhalers during his career. He explained that his symptoms worsened during the Vuelta, and he sought medical advice from the team doctor in order to increase his salbutamol dosage. Team Sky principal David Brailsford said the team will co-operate with the UCI to establish the cause of Froome’s elevated concentration.
- Chris Froome returns adverse analytical finding for salbutamol
- Will Chris Froome’s salbutamol result sink Team Sky?
- Vuelta a Espana organisers call for ‘extreme caution’ after Froome salbutamol result
- Nibali: Chris Froome salbutamol case is terrible for the sport
- Froome’s salbutamol case and what it means for him, Team Sky and cycling – Podcast
The World Anti-Doping Agency has regulations around the use of salbutamol, a bronchodialator (beta 2-agonist) used to treat asthma.
You can read more at Cyclingnews.com